Scientists test 'Double Radiation' attack on tough prostate cancer
NCT ID NCT05162573
Summary
This early-stage study tested whether adding a newer, targeted radiation drug (Lu-PSMA) to standard radiation therapy (EBRT) is safe and tolerable for men with prostate cancer that has spread to nearby lymph nodes. The goal was to see if this combination could better control the cancer while potentially reducing the need for long-term hormone therapy and its side effects. The study involved 14 participants to find the safest dose of the new drug combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Netherlands Cancer Institute
Amsterdam, 1066 CX, Netherlands
-
UMC Utrecht
Utrecht, 3508 GA, Netherlands
Conditions
Explore the condition pages connected to this study.